Literature DB >> 33480428

Changes in pulmonary function and their correlation with dose-volume parameters in patients undergoing stereotactic body radiotherapy for lung cancer.

Shinya Takemoto1,2, Yuta Shibamoto1, Chisa Hashizume3, Akifumi Miyakawa4, Taro Murai1, Takeshi Yanagi5, Chikao Sugie6, Aiko Nagai7.   

Abstract

It is desirable to estimate the degree of the decrease in pulmonary function before lung stereotactic body radiation therapy (SBRT) especially for patients with poor pulmonary function. The purpose of this study was to investigate whether decreases in pulmonary function after SBRT may be predicted from radiation dose-volume parameters. A total of 70 patients undergoing SBRT were evaluated for changes in pulmonary function. Of these, 67 had primary lung cancer and 3 had lung metastasis. Twenty-six (37%) patients had chronic obstructive pulmonary disease. Pulmonary function tests (PFTs) were performed shortly before and at 18-24 months after SBRT. Radiation pneumonitis was Grade 2 in 10 patients and Grade 3 in 1. Mean forced vital capacity (FVC) decreased from 2.67 to 2.51 L (P < 0.01) and mean forced expiratory volume in 1 s (FEV1) decreased from 1.80 to 1.72 L (P < 0.01). Planning target volume (PTV) was correlated with changes in FVC. Changes in percent predicted FVC were correlated with %V5Gy (% of lung volume receiving > 5 Gy) and %V40Gy. Although the correlation was not significant, the %V20Gy value was the closest to the percent reduction in predicted FVC; %V20Gy of 10% tended to be associated with ~10% reduction in predicted FVC. Patients with poor pulmonary function did not necessarily show greater decreases in each PFT parameter. Decreases in FVC and FEV1 were within previously reported ranges. PTV was associated with decreases in FVC. The %V20Gy value was closest to the percentage decrease in predicted FVC.
© The Author(s) 2021. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Entities:  

Keywords:  dose–volume parameters; lung cancer; pulmonary function test; stereotactic radiation therapy

Year:  2021        PMID: 33480428      PMCID: PMC7948829          DOI: 10.1093/jrr/rraa131

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  28 in total

1.  Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy.

Authors:  Atsuya Takeda; Tatsuji Enomoto; Naoko Sanuki; Hiroshi Handa; Yousuke Aoki; Yohei Oku; Etsuo Kunieda
Journal:  Chest       Date:  2013-01       Impact factor: 9.410

2.  Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors.

Authors:  Toshio Ohashi; Atsuya Takeda; Naoyuki Shigematsu; Etsuo Kunieda; Akitoshi Ishizaka; Junichi Fukada; Hossain M Deloar; Osamu Kawaguchi; Toshiaki Takeda; Kazuhiko Takemasa; Kouichi Isobe; Atsushi Kubo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

3.  Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis.

Authors:  Yukinori Matsuo; Fengshi Chen; Masatsugu Hamaji; Atsushi Kawaguchi; Nami Ueki; Yasushi Nagata; Makoto Sonobe; Satoshi Morita; Hiroshi Date; Masahiro Hiraoka
Journal:  Eur J Cancer       Date:  2014-09-30       Impact factor: 9.162

4.  Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.

Authors:  Yukinori Matsuo; Keiko Shibuya; Mitsuhiro Nakamura; Masaru Narabayashi; Katsuyuki Sakanaka; Nami Ueki; Ken Miyagi; Yoshiki Norihisa; Takashi Mizowaki; Yasushi Nagata; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-19       Impact factor: 7.038

5.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

Authors:  Robert Timmerman; Ronald McGarry; Constantin Yiannoutsos; Lech Papiez; Kathy Tudor; Jill DeLuca; Marvene Ewing; Ramzi Abdulrahman; Colleen DesRosiers; Mark Williams; James Fletcher
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

6.  Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.

Authors:  Matthias Guckenberger; Rainer J Klement; Larry L Kestin; Andrew J Hope; Jose Belderbos; Maria Werner-Wasik; Di Yan; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao; Inga S Grills
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-12       Impact factor: 7.038

7.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

8.  Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.

Authors:  Masaki Nakamura; Hideki Nishimura; Masao Nakayama; Hiroshi Mayahara; Haruka Uezono; Aya Harada; Naoki Hashimoto; Yasuo Ejima; Takeaki Ishihara; Ryohei Sasaki
Journal:  Br J Radiol       Date:  2016-11-02       Impact factor: 3.039

9.  Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results.

Authors:  Fumiya Baba; Yuta Shibamoto; Natsuo Tomita; Chisa Ikeya-Hashizume; Kyota Oda; Shiho Ayakawa; Hiroyuki Ogino; Chikao Sugie
Journal:  Radiat Oncol       Date:  2009-05-28       Impact factor: 3.481

Review 10.  Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?

Authors:  Yuta Shibamoto; Akifumi Miyakawa; Shinya Otsuka; Hiromitsu Iwata
Journal:  J Radiat Res       Date:  2016-03-22       Impact factor: 2.724

View more
  1 in total

1.  Statistical evaluation of the effectiveness of dual amplitude-gated stereotactic body radiotherapy using fiducial markers and lung volume.

Authors:  Yoshinori Tanabe; Hidekazu Tanaka
Journal:  Phys Imaging Radiat Oncol       Date:  2022-10-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.